• 1
    Trousseau A. Phlegmasia alba dolens. In: BaillierJB, ed. Clinique Medicale de l'Hotel-Dieu de Paris.2nd ed. London: New Sydenham Society; 1865: 3: 9495.
  • 2
    Levitan N,Dowlati A,Remick S, et al. Rates of initial and recurrent thromboembolic disease among patients with malignancy versus those without malignancy: the risk analysis using Medicare claims data. Medicine. 1999; 78: 285291.
  • 3
    Sorensen H,Mellemkjaer L,Steffensen F, et al. The risk of a diagnosis of cancer after primary deep venous thrombosis or pulmonary embolis. N Engl J Med. 1998; 338: 11691173.
  • 4
    Sorensen H,Mellemkjaer L,Olsen J, et al. Prognosis of cancers associated with venous thromboembolism. N Engl J Med. 200; 343: 18461850.
  • 5
    Fisher B,Castantino J,Redmond C, et al. A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negate breast cancer who have estrogen-receptor-positive tumors. N Engl J Med. 1989; 320: 479484.
  • 6
    Fisher B,Digman J,Wolmark N, et al. Tamoxifen and chemotherapy for lymph node-negative, estrogen receptor-positive breast cancer. J Natl Cancer Inst. 1997; 89: 16731682.
  • 7
    Lee A,Levine M. The thrombophiliic state induced by therapeutic agents in cancer patients. Semin Thromb Hemost. 1999; 25: 137145.
  • 8
    Klerk CP,Smorenburg SM,Otten HM, et al. The effect of low molecular weight heparin on survival in patients with advanced malignancy. J Clin Oncol. 2005; 23: 21302135.
  • 9
    Shah M,Ilson D,Kelson D. Thromboembolic events in gastric cancer: high incidence in patients receiving irinotecan- and bevacizumab-based therapy [letter]. J Clin Oncol. 2005; 23: 25742526.
  • 10
    National Cancer Institute Website. Available at URL: Accessed August 29, 2005.
  • 11
    Rothenberg ML,Meropol NJ,Poplin EA, et al. Mortality associated with irinotecan plus bolus fluorouracil/leucovorin: summary findings of an independent panel. J Clin Oncol. 2001; 19: 38013807.
  • 12
    Skillings JR,Johnson DH,Miller K, et al. Arterial thromboembolic events (ATEs) in a pooled analysis of 5 randomized, controlled trials (RCTs) of bevacizumab (BV) with chemotherapy. J Clin Oncol. 2005; 23( suppl): 196s. Abstract 3019.
  • 13
    Palareti G,Cosmi B,Legnani C, et al. D-dimer testing to determine duration of anticoagulation therapy. N Engl J Med. 2006; 355: 1781790.